By Dr John James Moore

Journal articles

Snowden JA; Saccardi R; Orchard K; Ljungman P; Duarte RF; Labopin M; McGrath E; Brook N; de Elvira CR; Gordon D; Poirel HA; Ayuk F; Beguin Y; Bonifazi F; Gratwohl A; Milpied N; Moore J; Passweg J; Rizzo JD; Spellman SR; Sierra J; Solano C; Sanchez-Guijo F; Worel N; Gusi A; Adams G; Balan T; Baldomero H; Macq G; Marry E; Mesnil F; Oldani E; Pearce R; Perry J; Raus N; Schanz U; Tran S; Wilcox L; Basak GW; Chabannon C; Corbacioglu S; Dolstra H; Kuball J; Mohty M; Lankester A; Montoto S; Nagler A; Styczynski J; Yakoub-Agha I; de Latour RP; Kroeger N; Brand R; de Wreede LC; van Zwet E; Putter H, 2020, 'Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) (Bone Marrow Transplantation, (2020), 55, 4, (681-694), 10.1038/s41409-019-0718-7)', Bone Marrow Transplantation, 55, pp. 838 - 839, http://dx.doi.org/10.1038/s41409-019-0740-9

Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R, 2020, 'Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial', The Lancet Haematology, 7, pp. e100 - e111, http://dx.doi.org/10.1016/S2352-3026(19)30220-0

Sharrack B; Saccardi R; Alexander T; Badoglio M; Burman J; Farge D; Greco R; Jessop H; Kazmi M; Kirgizov K; Labopin M; Mancardi G; Martin R; Moore J; Muraro PA; Rovira M; Sormani MP; Snowden JA; McGrath E; Bambi F; Sanchez-Guijo F; Worel N; Badolglio M; Abinun M; Arnold R; Brierley C; Castilla-Llorente C; Cooper N; Daikeler T; del Papa N; Finke J; Reax R; Hagglund H; Henes J; Hiepe F; Kiely D; Mancardi G; Marjanovic Z; Martin T; Ma D; Miller P; Oliveira MC; Polushin A; Onida F; Simoes B; Puyade M; Resnick I; Saif M; Sakellari I; Snarski E; Scherer HU; Sossa C; de Vries-Bouwstra J; Wulffraat N; Zaccara E, 2020, 'Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)', Bone Marrow Transplantation, 55, pp. 283 - 306, http://dx.doi.org/10.1038/s41409-019-0684-0

Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA, 2019, 'Autologous haematopoietic stem cell therapy for multiple sclerosis: A review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation', Current Opinion in Supportive and Palliative Care, 13, pp. 394 - 401, http://dx.doi.org/10.1097/SPC.0000000000000466

Abeysinghe P; Morawaka L; Gunasekara S; Suresh S; Jayathilake P; Udara P; Siriwardena P; Milliken S; Moore J; Ma D, 2019, 'Country Report: The Report of Transplant Activity and Outcome During the First 12 Months at the First National Hematopoietic Stem Cell Transplant Center in Sri Lanka.', Blood Cell Ther, 2, pp. 50 - 53, http://dx.doi.org/10.31547/bct-2019-007

Saccardi R; Badoglio M; Burman J; Helbig G; Kazmi MA; Mancardi G; Mielke S; Moore J; Muraro P; Sanz J; Sharrack B; Smilowski M; Sormani MP; Snowden JA, 2019, 'BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society', Blood, 134, pp. 3313 - 3313, http://dx.doi.org/10.1182/blood-2019-125233

Roy J; Panzarella T; Couban S; Couture F; Devins GM; Elemary M; Foley SR; Gallagher G; Kuruvilla J; Lee SJ; Moore J; Nevill TJ; Popradi G; Schultz KR; Szwajcer D; Toze CL; Walker I, 2019, 'Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial', Blood, 134, pp. 875 - 875, http://dx.doi.org/10.1182/blood-2019-123275

Kennedy GA; Tey S-K; Curley C; Butler JP; Misra A; Subramoniapillai E; Morton J; Durrant S; Hendon AS; Moore J; Ritchie D; Gottlieb D; Cooney J; Buizen L; Paul SK; Hill GR, 2019, 'Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation', Blood, 134, pp. 368 - 368, http://dx.doi.org/10.1182/blood-2019-126285

Jessop H; Farge D; Saccardi R; Alexander T; Rovira M; Sharrack B; Greco R; Wulffraat N; Moore J; Kazmi M; Badoglio M; Adams G; Verhoeven B; Murray J; Snowden JA, 2019, 'General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE)', Bone Marrow Transplantation, 54, pp. 933 - 942, http://dx.doi.org/10.1038/s41409-019-0430-7

Massey Jennifer C ; Moore John J ; Milliken Samuel T ; Ma David D F , 2019, 'Autologous hematopoietic stem cell transplant for autoimmune diseases: evolution,evidence of efficacy, and real-world economics.', Blood Cell Ther, 2, pp. 12 - 21, http://dx.doi.org/10.31547/bct-2018-009

Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF, 2019, 'Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis', Journal of Neurology, Neurosurgery and Psychiatry, 90, pp. 514 - 521, http://dx.doi.org/10.1136/jnnp-2018-319446

Dyer G; Gilroy N; Brice L; Kabir M; Gottlieb D; Huang G; Hogg M; Brown L; Greenwood M; Larsen SR; Moore J; Hertzberg M; Tan J; Ward C; Kerridge I, 2019, 'A survey of infectious diseases and vaccination uptake in long-term hematopoietic stem cell transplant survivors in Australia', Transplant Infectious Disease, 21, http://dx.doi.org/10.1111/tid.13043

McCarthy R-L; McNamee N; Copelin B; Mills G; Wong S; Qiu MR; Earls P; Milliken S; Hamad N; Fay K; Lukeis R; Parker A; Moore J, 2019, 'A case series of langerhans cell histiocytosis with braf testing', Pathology, 51, pp. S92 - S92, http://dx.doi.org/10.1016/j.pathol.2018.12.243

Ma CKK; García-Cadenas I; Fox ML; Ai S; Nivison-Smith I; Milliken ST; Dodds A; Fay K; Ma DDF; Martino R; Sierra J; Moore J, 2018, 'Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis', Bone Marrow Transplantation, 53, pp. 1478 - 1482, http://dx.doi.org/10.1038/s41409-018-0215-4

Ting YS; Smith SABC; Brown DA; Dodds AJ; Fay KC; Ma DDF; Milliken S; Moore JJ; Sewell WA, 2018, 'CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry', International Journal of Laboratory Hematology, 40, pp. 533 - 539, http://dx.doi.org/10.1111/ijlh.12857

Dyer G; Brice L; Schifter M; Gilroy N; Kabir M; Hertzberg M; Greenwood M; Larsen SR; Moore J; Gottlieb D; Huang G; Hogg M; Brown L; Tan J; Ward C; Kerridge I, 2018, 'Oral health and dental morbidity in long-term allogeneic blood and marrow transplant survivors in Australia', Australian Dental Journal, 63, pp. 312 - 319, http://dx.doi.org/10.1111/adj.12627

Dyer G; Brice L; Gilroy N; Kabir M; Hertzberg M; Greenwood M; Larsen SR; Moore J; Gottlieb D; Huang G; Hogg M; Brown L; Tan J; Ward C; Kerridge I, 2018, 'Changes to work status and household income of long-term allogeneic blood and marrow transplant survivors in New South Wales, Australia', Bone Marrow Transplantation, 53, pp. 926 - 931, http://dx.doi.org/10.1038/s41409-018-0098-4

Massey JC; Sutton IJ; Ma DDF; Moore JJ, 2018, 'Regenerating immunotolerance in multiple sclerosis with autologous hematopoietic stem cell transplant', Frontiers in Immunology, 9, http://dx.doi.org/10.3389/fimmu.2018.00410

Lim ABM; Curley C; Fong CY; Bilmon I; Beligaswatte A; Purtill D; Getta B; Johnston AM; Armytage T; Collins M; Mason K; Fielding K; Greenwood M; Gibson J; Hertzberg M; Wright M; Lewis I; Moore J; Curtis D; Szer J; Kennedy G; Ritchie D, 2018, 'Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse', Internal Medicine Journal, 48, pp. 276 - 285, http://dx.doi.org/10.1111/imj.13522

Abeysinghe P; Morawaka L; Gunasekara S; Suresh S; Udara PHSP; Siriwardena PPR; Milliken S; Ma DDF; Moore J, 2018, 'Working together: Establishment of the first national hematopoietic stem cell transplantation (HSCT) center in Sri Lanka', Blood Advances, 2, pp. 46 - 49, http://dx.doi.org/10.1182/bloodadvances.2018GS110686

Snowden JA; Badoglio M; Labopin M; Giebel S; McGrath E; Marjanovic Z; Burman J; Moore J; Rovira M; Wulffraat NM; Kazmi M; Greco R; Snarski E; Kozak T; Kirgizov K; Alexander T; Bader P; Saccardi R; Farge D, 2017, 'Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases', Blood Advances, 1, pp. 2742 - 2755, http://dx.doi.org/10.1182/bloodadvances.2017010041

Bradstock KF; Link E; Iulio JD; Szer J; Marlton P; Wei AH; Enno A; Schwarer A; Lewis ID; D’Rozario J; Coyle L; Cull G; Campbell P; Leahy MF; Hahn U; Cannell P; Tiley C; Lowenthal RM; Moore J; Cartwright K; Cunningham I; Taper J; Grigg A; Roberts AW; Benson W; Hertzberg M; Deveridge S; Rowlings P; Mills AK; Gill D; Bardy P; Campbell L; Seymour JF, 2017, 'Idarubicin dose escalation during consolidation therapy for adult acute myeloid leukemia', Journal of Clinical Oncology, 35, pp. 1678 - 1685, http://dx.doi.org/10.1200/JCO.2016.70.6374

Brice L; Gilroy N; Dyer G; Kabir M; Greenwood M; Larsen S; Moore J; Kwan J; Hertzberg M; Brown L; Hogg M; Huang G; Tan J; Ward C; Gottlieb D; Kerridge I, 2017, 'Haematopoietic stem cell transplantation survivorship and quality of life: is it a small world after all?', Supportive Care in Cancer, 25, pp. 421 - 427, http://dx.doi.org/10.1007/s00520-016-3418-5

Smith J; Poon C; Gilroy N; Kabir M; Brice L; Dyer G; Hogg M; Greenwood M; Moore J; Hertzberg M; Brown L; Tan J; Huang G; Kwan J; Larsen S; Ward C; Kerridge I, 2017, 'Nutritional issues and body weight in long-term survivors of allogeneic blood and marrow transplant (BMT) in NSW Australia', Supportive Care in Cancer, 25, pp. 137 - 144, http://dx.doi.org/10.1007/s00520-016-3398-5

Lindsay J; Kabir M; Gilroy N; Dyer G; Brice L; Moore J; Greenwood M; Hertzberg M; Gottlieb D; Larsen SR; Hogg M; Brown L; Huang G; Tan J; Ward C; Kerridge I; Gilroy N, 2016, 'Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia', Cancer Medicine, 5, pp. 3606 - 3614, http://dx.doi.org/10.1002/cam4.889

Gifford G; Gilroy N; Dyer G; Brice L; Kabir M; Greenwood M; Larsen S; Moore J; Gottlieb D; Hertzberg M; Kwan J; Huang G; Tan J; Brown L; Hogg M; Ward C; Kerridge I, 2016, 'The experience of survival following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia', Bone Marrow Transplantation, 51, pp. 1361 - 1368, http://dx.doi.org/10.1038/bmt.2016.135

Dyer G; Larsen SR; Gilroy N; Brice L; Greenwood M; Hertzberg M; Kabir M; Brown L; Hogg M; Huang G; Moore J; Gottlieb D; Kwan J; Tan J; Ward C; Kerridge I, 2016, 'Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT)', Cancer Medicine, 5, pp. 1702 - 1716, http://dx.doi.org/10.1002/cam4.729

Oliveira MC; Labopin M; Henes J; Moore J; Papa ND; Cras A; Sakellari I; Schroers R; Scherer HU; Cuneo A; Kyrcz-Krzemien S; Daikeler T; Alexander T; Finke J; Badoglio M; Simoes B; Snowden JA; Farge D, 2016, 'Erratum: Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? (Bone Marrow Transplantation (2016) 51 (501-505) DOI: 10.1038/bmt.2015.299)', Bone Marrow Transplantation, 51, pp. 889, http://dx.doi.org/10.1038/bmt.2016.126

Oliveira MC; Labopin M; Henes J; Moore J; Papa ND; Cras A; Sakellari I; Schroers R; Scherer HU; Cuneo A; Kyrcz-Krzemien S; Daikeler T; Alexander T; Finke J; Badoglio M; Simões B; Snowden JA; Farge D, 2016, 'Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients?', Bone Marrow Transplantation, 51, pp. 501 - 505, http://dx.doi.org/10.1038/bmt.2015.299

Dyer G; Gilroy N; Brown L; Hogg M; Brice L; Kabir M; Greenwood M; Larsen SR; Moore J; Hertzberg M; Kwan J; Huang G; Tan J; Ward C; Kerridge I, 2016, 'What They Want: Inclusion of Blood and Marrow Transplanation Survivor Preference in the Development of Models of Care for Long-Term Health in Sydney, Australia', Biology of Blood and Marrow Transplantation, 22, pp. 731 - 743, http://dx.doi.org/10.1016/j.bbmt.2015.12.019

Dyer G; Gilroy N; Bradford J; Brice L; Kabir M; Greenwood M; Larsen SR; Moore J; Hertzberg M; Kwan J; Brown L; Hogg M; Huang G; Tan J; Ward C; Kerridge I, 2016, 'A survey of fertility and sexual health following allogeneic haematopoietic stem cell transplantation in New South Wales, Australia', British Journal of Haematology, 172, pp. 592 - 601, http://dx.doi.org/10.1111/bjh.13872

Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R, 2016, 'Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial', The Lancet Oncology, 17, pp. 164 - 173, http://dx.doi.org/10.1016/S1470-2045(15)00462-3

Rebeiro P; Moore J, 2016, 'The role of autologous haemopoietic stem cell transplantation in the treatment of autoimmune disorders', Internal Medicine Journal, 46, pp. 17 - 28, http://dx.doi.org/10.1111/imj.12944

Shen S; Xu N; Klamer G; Ko KH; Khoo M; Ma D; Moore J; O'Brien TA; Dolnikov A, 2015, 'Small-molecule inhibitor of glycogen synthase kinase 3β 6-bromoindirubin-3-oxime inhibits hematopoietic regeneration in stem cell recipient mice', Stem Cells and Development, 24, pp. 724 - 736, http://dx.doi.org/10.1089/scd.2014.0230

Snarski E; Snowden JA; Oliveira MC; Simoes B; Badoglio M; Carlson K; Burman J; Moore J; Rovira M; Clark RE; Saiz A; Hadj-Khelifa S; Tan J; Crescimanno A; Musso M; Martin T; Farge D, 2015, 'Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: A retrospective study of the EBMT autoimmune diseases working party (ADWP)', Bone Marrow Transplantation, 50, pp. 216 - 220, http://dx.doi.org/10.1038/bmt.2014.248

Alexander T; Bondanza A; Muraro PA; Greco R; Saccardi R; Daikeler T; Kazmi M; Hawkey C; Simoes BP; Leblanc K; Fibbe WE; Moore J; Snarski E; Martin T; Hiepe F; Velardi A; Toubert A; Snowden JA; Farge D, 2015, 'SCT for severe autoimmune diseases: Consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking', Bone Marrow Transplantation, 50, pp. 173 - 180, http://dx.doi.org/10.1038/bmt.2014.251

Iland HJ; Collins M; Bradstock K; Supple S; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell L; Hugman A; Reynolds J; Di Lulio J; Campbell T; Taylor K; Filshie R; Seldon M; Tape J; Szer J; Moore JJ; Bashford J; Seymour JF, 2015, 'Impact of incorporating arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia: final analysis of th Australian Leukaemia and Lymphoma Group (ALLG) APML4 non-randomised phase II trial', Lancet (North American Edition), 9, pp. e357 - e366

Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ, 2015, 'Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors', Journal of Heart and Lung Transplantation, 34, pp. 1406 - 1414, http://dx.doi.org/10.1016/j.healun.2015.05.021

Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R, 2015, 'Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial', The Lancet Oncology, http://dx.doi.org/10.1016/S1470-2045(15)00462-3

Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF, 2015, 'Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomised phase 2 trial', The Lancet Haematology, 2, pp. e357 - e366, http://dx.doi.org/10.1016/S2352-3026(15)00115-5

Walker I; Schultz KR; Toze CL; Kerr HM; Moore J; Szwajcer D; Foley SR; Kuruvilla J; Panzarella T; Couture F; Roy J; Couban S; Devins G; Popradi G; Lee SJ; Tay J; Nevill TJ; Elemary M; Gallagher G, 2014, 'Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial', BLOOD, 124, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349242702187&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Khoo MLM; Carlin SM; Lutherborrow MA; Jayaswal V; Ma DDF; Moore JJ, 2014, 'Gene profiling reveals association between altered Wnt signaling and loss of T-cell potential with age in human hematopoietic stem cells', Aging Cell, 13, pp. 744 - 754, http://dx.doi.org/10.1111/acel.12229

Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142

Subramaniam K; Yeung D; Grimpen F; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J, 2014, 'Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks?', Internal Medicine Journal, 44, pp. 287 - 290, http://dx.doi.org/10.1111/imj.12363

Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23

Snarski E; Snowden JA; Badoglio M; Carlson K; Burman J; Oliveira MC; Moore J; Tan J; Rovira M; Clark RE; Saiz A; Khelifa SH; Crescimanno A; Laing L; Musso M; Martin T; Farge D, 2013, 'Outcome Of Pregnancy After Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Autoimmune Diseases (AD): A Retrospective Study Of The EBMT Autoimmune Diseases Working Party (ADWP)', Blood, 122, pp. 4640 - 4640, http://dx.doi.org/10.1182/blood.v122.21.4640.4640

Zimmermann H; Choquet S; Moore J; Salles G; Morschhauser F; Lamy T; Jaccard A; Horst HA; Leithäuser M; Dührsen U; Reinke P; Lebranchu Y; Neuhaus R; Lehmkuhl H; Tarella C; Schlattmann P; Riess H; Leblond V; Trappe RU, 2013, 'Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial', Leukemia, 27, pp. 2102 - 2105, http://dx.doi.org/10.1038/leu.2013.110

Subramaniam K; Grimpen F; Yeung D; Joseph J; Fay K; Buckland M; Talaulikar D; Elijah J; Clarke AC; Pavli P; Moore J, 2013, 'Immunosuppressive agents and the risk of hepatosplenic gamma delta-T cell lymphoma (HSTCL): Is the risk increased by concomitant use of anti-TNFs?', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28, pp. 95 - 96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324106900203&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zimmermann H; Choquet S; Dierickx D; Dreyling MH; Moore J; Valentin A; Striefler JK; Riess H; Leblond V; Trappe RU, 2013, 'Early and late posttransplant lymphoproliferative disorder after lung transplantation-34 cases from the European PTLD network', Transplantation, 96, http://dx.doi.org/10.1097/TP.0b013e31829b0868

Carlin SM; Ma DD; Moore JJ, 2013, 'T-cell potential of human adult and cord blood hemopoietic stem cells expanded with the use of aryl hydrocarbon receptor antagonists', Cytotherapy, 15, pp. 224 - 230, http://dx.doi.org/10.1016/j.jcyt.2012.10.014

Back to profile page